Printer Friendly

RUDER FINN ESTABLISHES BIOTECHNOLOGY UNIT; NEW GROUP PROVIDES EXPERTISE IN HEALTHCARE, AGRICULTURE, SCIENCE AND CAPITAL MARKETS

 NEW YORK, Dec. 3 /PRNewswire/ -- Building upon its leadership in healthcare and investor/corporate relations services, as well as its burgeoning agricultural business, Ruder Finn is establishing the Biotechnology Group, a separate unit to serve the biotechnology sector.
 Peter Steinerman, vice president of Ruder Finn's Healthcare Group, heads up the new division. With a background in biology and medical research, Steinerman has worked with clients such as Genetics Institute, Cortex and Novo Nordisk. Steinerman will work closely with Robert Ferris, president of R-F Corporate/Investor Relations, and Denis Peters, managing director of R-F/Europe.
 The Biotechnology Group will provide counsel and services in media relations, corporate positioning and identity, professional education, product promotion and introduction, FDA and EPA advisory hearings, scientific publicity, crisis management and preparedness, and investor and capital market communications programs.
 Because many biotechnology companies enter into joint ventures and strategic partnerships with companies around the world, Peter Finn, chairman of Ruder Finn's executive committee, says the global perspective Ruder Finn brings from its presence and experience in Europe enables the Biotechnology Group to educate clients about strategic growth and capital market opportunities.
 "With our unique dual understanding of biotechnology and the global capital markets, we assist start-up companies headquartered outside the U.S. to plan and execute a capital formation strategy in the markets where reception is highest for the biotechnological sciences," Finn says. "Moreover, our multi-cultural communications professionals in Europe plan and execute successful pan-European communications programs to assist biotechnology companies to address the many EC-level issues pertaining to biotechnology in both the agricultural and pharmaceutical sectors."
 Steinerman says that by establishing this separate specialty, Ruder Finn is able to offer smaller biotechnology companies the same kinds of specialized services that only larger, blue-chip companies have been able to access. "The new unit's expertise is helping biopharmaceutical companies demonstrate the value of their products to regulators, potential prescribers and prospective patients," he says.
 Ruder Finn is one of the nation's oldest and largest independent public relations companies, with offices in New York City, Washington, D.C., Los Angeles, Chicago, Raleigh, London, Paris, Stockholm and Japan. Working with biotechnology start-up companies, as well as biotechnology units of major multinational pharmaceutical companies, Ruder Film has implemented many successful campaigns for promoting pharmaceutical, agricultural and food stock technologies. Other Ruder Finn clients include GenVec and Ortho Diagnostic Systems.
 -0- 12/3/93
 /CONTACT: Dena Merriam of Ruder Finn, 212-593-6417/


CO: Ruder Finn ST: New York IN: SU: PDT

SH-TW -- NY051 -- 0309 12/03/93 15:12 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 3, 1993
Words:418
Previous Article:TENNECO NAMES WILLIAM L. WEISS TO BOARD OF DIRECTORS
Next Article:KNOGO REPORTS 47% EARNINGS INCREASE FOR FIRST NINE MONTHS
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters